PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 178 filers reported holding PUMA BIOTECHNOLOGY INC in Q1 2018. The put-call ratio across all filers is 0.98 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $38,000 | -11.6% | 4,400 | +8.6% | 0.00% | – |
| Q3 2019 | $43,000 | +65.4% | 4,051 | +97.1% | 0.00% | – |
| Q2 2019 | $26,000 | -56.7% | 2,055 | +32.2% | 0.00% | – |
| Q1 2019 | $60,000 | +252.9% | 1,554 | +85.0% | 0.00% | – |
| Q4 2018 | $17,000 | -69.6% | 840 | -31.1% | 0.00% | -100.0% |
| Q3 2018 | $56,000 | +300.0% | 1,220 | +404.1% | 0.00% | – |
| Q2 2018 | $14,000 | -17.6% | 242 | -2.4% | 0.00% | – |
| Q1 2018 | $17,000 | -56.4% | 248 | -37.4% | 0.00% | -100.0% |
| Q4 2017 | $39,000 | +2.6% | 396 | +23.4% | 0.00% | 0.0% |
| Q3 2017 | $38,000 | +1166.7% | 321 | +903.1% | 0.00% | – |
| Q2 2017 | $3,000 | +200.0% | 32 | 0.0% | 0.00% | – |
| Q1 2017 | $1,000 | -93.8% | 32 | -94.0% | 0.00% | – |
| Q4 2016 | $16,000 | +700.0% | 532 | +1137.2% | 0.00% | – |
| Q3 2016 | $2,000 | – | 43 | +95.5% | 0.00% | – |
| Q2 2016 | $0 | – | 22 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| EcoR1 Capital, LLC | 2,536,156 | $21,405,000 | 2.24% |
| Palo Alto Investors LP | 1,396,163 | $11,784,000 | 0.99% |
| Camber Capital Management LP | 1,950,000 | $16,458,000 | 0.98% |
| TANG CAPITAL MANAGEMENT LLC | 800,000 | $6,752,000 | 0.95% |
| Capital Impact Advisors, LLC | 147,303 | $1,243,000 | 0.52% |
| Sofinnova Investments, Inc. | 638,026 | $5,385,000 | 0.50% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 963,212 | $8,130,000 | 0.26% |
| RICE HALL JAMES & ASSOCIATES, LLC | 466,482 | $3,937,000 | 0.22% |
| PDT Partners, LLC | 204,238 | $1,724,000 | 0.14% |
| Eversept Partners, LP | 58,251 | $491,638 | 0.12% |